References
- Gennari A, André F, Barrios CH, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021 Dec;32(12):1475–1495. DOI:https://doi.org/10.1016/j.annonc.2021.09.019.
- Grizzi G, Ghidini M, Botticelli A, et al. Strategies for increasing the effectiveness of aromatase inhibitors in locally advanced breast cancer: an evidence-based review on current options. Cancer Manag Res. 2020;12:675–686.
- Fusco N, Malapelle U, Fassan M, et al. PIK3CA mutations as a molecular target for hormone receptor-positive, HER2-negative metastatic breast cancer. Front Oncol. 2021;11:562.
- Criscitiello C, Corti C, Pravettoni G, et al. Managing side effects of immune checkpoint inhibitors in breast cancer. Crit Rev Oncol Hematol. 2021 Jun;162:103354.
- Criscitiello C, Guerini-Rocco E, Viale G, et al. Immunotherapy in breast cancer patients: a focus on the use of the currently available biomarkers in oncology. Anticancer Agents Med Chem. 2021 Jul 6;22(4):787–800.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7–30.
- Fusco N, Sajjadi E, Venetis K, et al. Low-risk triple-negative breast cancers: clinico-pathological and molecular features. Crit Rev Oncol Hematol. 2022 Feb;22:103643.
- Corso G, D’Ecclesiis O, Magnoni F, et al. Metaplastic breast cancers and triple-negative breast cancers of no special type: are they prognostically different? A systematic review and meta-analysis. Eur J Cancer Prev. 2021 Dec 15;Publish Ahead of Print: https://doi.org/10.1097/CEJ.0000000000000733
- Masuda N, Lee SJ, Ohtani S, et al. Adjuvant Capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017 Jun 1 376(22):2147–2159. https://doi.org/10.1056/NEJMoa1612645
- Corti C, Nicolò E, Curigliano G. Novel immune targets for the treatment of triple-negative breast cancer. Expert Opin Ther Targets. 2021 Oct;25(10):815–834.
- Tutt A, Garber JE, Kaufman B, et al. OlympiA: a phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer. J clin oncol. 2021 [2021 June 20];39(18):LBA1–LBA1. DOI:https://doi.org/10.1200/JCO.2021.39.15_suppl.LBA1.
- Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1 30(4):558–566. https://doi.org/10.1093/annonc/mdz012
- Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018 Aug 23 379(8):753–763. https://doi.org/10.1056/NEJMoa1802905
- Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019 Feb 21 380(8):741–751. https://doi.org/10.1056/NEJMoa1814213
- Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021 Apr 22 384(16):1529–1541. https://doi.org/10.1056/NEJMoa2028485
- Pagni F, Guerini-Rocco E, Schultheis AM, et al. targeting immune-related biological processes in solid tumors: we do need biomarkers. Int J Mol Sci. 2019 Nov 1 20(21):5452. https://doi.org/10.3390/ijms20215452
- Sajjadi E, Venetis K, Scatena C, et al. Biomarkers for precision immunotherapy in the metastatic setting: hope or reality? Ecancermedicalscience. 2020;14:1150.
- Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 Jan;21(1):44–59. DOI:https://doi.org/10.1016/S1470-2045(19)30689-8.
- Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020 Dec 5 396(10265):1817–1828. https://doi.org/10.1016/S0140-6736(20)32531-9
- Bianchini G, De Angelis C, Licata L, et al. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2022 Feb;19(2):91–113. DOI:https://doi.org/10.1038/s41571-021-00565-2.
- Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020 Feb 27 382(9):810–821. https://doi.org/10.1056/NEJMoa1910549
- Tarantino P, Corti C, Schmid P, et al. Immunotherapy for early triple negative breast cancer: research agenda for the next decade. npj breast cancer. NPJ Breast Cancer. 2022 [2022 February 18];8(1):23. DOI:https://doi.org/10.1038/s41523-022-00386-1.
- Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019 Aug 1 30(8):1279–1288. https://doi.org/10.1093/annonc/mdz158
- Gianni L, Huang C-S, Egle D, et al. Abstract GS3-04: pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 michelangelo randomized study. Cancer Res. 2020;80(4_Supplement):GS3-04-GS3-04.
- Winer EP, Lipatov O, Im S-A, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Apr;22(4):499–511. DOI:https://doi.org/10.1016/S1470-2045(20)30754-3.
- Venetis K, Invernizzi M, Sajjadi E, et al. Cellular immunotherapy in breast cancer: the quest for consistent biomarkers. Cancer Treat Rev. 2020 Nov;90:102089.
- Criscitiello C, Vingiani A, Maisonneuve P, et al. Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer. Breast Cancer Res Treat. 2020 Sep;183(2):347–354. DOI:https://doi.org/10.1007/s10549-020-05771-7.
- Gao G, Wang Z, Qu X, et al. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis. BMC Cancer. 2020 Mar 4 20(1):179. https://doi.org/10.1186/s12885-020-6668-z
- Rooney MS, Shukla SA, Wu CJ, et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015 Jan 15 160(1–2):48–61. https://doi.org/10.1016/j.cell.2014.12.033
- Loi S, Drubay D, Adams S, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol. 2019;37(7):559–569.
- Ibrahim EM, Al-Foheidi ME, Al-Mansour MM, et al. The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis. Breast Cancer Res Treat. 2014 Dec;148(3):467–476. DOI:https://doi.org/10.1007/s10549-014-3185-2.
- Adams S, Gatti-Mays ME, Kalinsky K, et al. Current landscape of immunotherapy in breast cancer: a review. JAMA Oncol. 2019 Aug 1 5(8):1205–1214. https://doi.org/10.1001/jamaoncol.2018.7147
- Dieci MV, Miglietta F, Guarneri V. Immune Infiltrates in Breast Cancer: recent Updates and Clinical Implications. Cells. 2021 Jan 23; 10(2):223. https://doi.org/10.3390/cells10020223
- Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011 Jul;121(7):2750–2767. DOI:https://doi.org/10.1172/JCI45014.
- Lehmann BD, Jovanović B, Chen X, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One. 2016;11(6):e0157368. DOI:https://doi.org/10.1371/journal.pone.0157368.
- Bareche Y, Buisseret L, Gruosso T, et al. Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach. J Natl Cancer Inst. 2020 Jul 1 112(7):708–719. https://doi.org/10.1093/jnci/djz208
- Karn T, Jiang T, Hatzis C, et al. Association between genomic metrics and immune infiltration in triple-negative breast cancer. JAMA Oncol. 2017 Dec 1 3(12):1707–1711. https://doi.org/10.1001/jamaoncol.2017.2140
- Wellenstein MD, Coffelt SB, Duits DEM, et al. Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis. Nature. 2019 Aug;572(7770):538–542. DOI:https://doi.org/10.1038/s41586-019-1450-6.
- Mehta AK, Cheney EM, Hartl CA, et al. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nat Cancer. 2021 Jan;2(1):66–82. DOI:https://doi.org/10.1038/s43018-020-00148-7.
- Tarantino P, Antonarelli G, Ascione L, et al. Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development. Expert Opin Investig Drugs. 2021 Sep;26:1–15.
- Cassetta L, Fragkogianni S, Sims AH, et al. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. Cancer Cell. 2019 Apr 15 35(4):588–602.e10. https://doi.org/10.1016/j.ccell.2019.02.009
- Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol. 2019 Jan 1 5(1):74–82. https://doi.org/10.1001/jamaoncol.2018.4224
- Milone MC, Xu J, Chen SJ, et al. Engineering enhanced CAR T-cells for improved cancer therapy Nat Cancer. 2021 Aug;2(8):780–793. https://doi.org/https://doi.org/10.1038/s43018-021-00241-5
- Xie Y, Hu Y, Zhou N, et al. CAR T-cell therapy for triple-negative breast cancer: where we are. Cancer Lett. 2020 Oct 28;491:121–131. https://doi.org/10.1016/j.canlet.2020.07.044.
- Schaft N. The landscape of CAR-T cell clinical trials against solid tumors-a comprehensive overview. Cancers (Basel). 2020 Sep 9; 12(9):2567. https://doi.org/10.3390/cancers12092567
- Chmielewski M, Abken H. TRUCKS, the fourth-generation CAR T cells: current developments and clinical translation ADVANCES IN CELL AND GENE THERAPY. 2020;e84. https://doi.org/https://doi.org/10.1002/acg2.84
- Bagley SJ, O’Rourke DM. Clinical investigation of CAR T cells for solid tumors: lessons learned and future directions. Pharmacol Ther. 2020 Jan;205:107419.
- Corti C, Giugliano F, Nicolò E, et al. Antibody-drug conjugates for the treatment of breast cancer. Cancers (Basel). 2021 Jun 9 13(12):2898. https://doi.org/10.3390/cancers13122898
- Abbott RC, Cross RS, Jenkins MR. Finding the keys to the CAR: identifying novel target antigens for T cell redirection immunotherapies. Int J Mol Sci. 2020 Jan 14; 21(2):515. https://doi.org/10.3390/ijms21020515
- Dees S, Ganesan R, Singh S, et al. Emerging CAR-T cell therapy for the treatment of triple-negative breast cancer. Mol Cancer Ther. 2020 Dec;19(12):2409–2421. DOI:https://doi.org/10.1158/1535-7163.MCT-20-0385.
- Hong R, Hu Y, Huang H. Biomarkers for chimeric antigen receptor T cell therapy in acute lymphoblastic leukemia: prospects for personalized management and prognostic prediction. Front Immunol. 2021;12:627764.
- Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, version 1.2019,nccn clinical practice guidelines in oncology. J Natl Compr Cancer Network. 2019 [11 Mar. 2019];17(3):255–289. DOI:https://doi.org/10.6004/jnccn.2019.0013.
- Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019 Jan;20(1):31–42. DOI:https://doi.org/10.1016/S1470-2045(18)30864-7.
- Kochenderfer JN, Somerville RPT, Lu T, et al. lymphoma remissions caused by anti-cd19 chimeric antigen receptor t cells are associated with high serum interleukin-15 levels. J Clin Oncol. 2017 Jun 1 35(16):1803–1813. https://doi.org/10.1200/JCO.2016.71.3024
- Rossi J, Paczkowski P, Shen YW, et al. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. Blood. 2018 Aug 23 132(8):804–814. https://doi.org/10.1182/blood-2018-01-828343
- Hirayama AV, Gauthier J, Hay KA, et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood. 2019 Apr 25 133(17):1876–1887. https://doi.org/10.1182/blood-2018-11-887067
- Nazha B, Inal C, Owonikoko TK. Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy. Front Oncol. 2020;10:1000.
- Seitz CM, Schroeder S, Knopf P, et al. GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells. Oncoimmunology. 2020;9(1):1683345. DOI:https://doi.org/10.1080/2162402X.2019.1683345.
- Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011 Dec 1 118(23):6050–6056. https://doi.org/10.1182/blood-2011-05-354449
- Wallstabe L, Göttlich C, Nelke LC, et al. ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models. JCI Insight. 2019 Sep 19;4(18). https://doi.org/10.1172/jci.insight.126345.
- Chien HP, Ueng SH, Chen SC, et al. Expression of ROR1 has prognostic significance in triple negative breast cancer. Virchows Arch. 2016 May;468(5):589–595. DOI:https://doi.org/10.1007/s00428-016-1911-3.
- Hudecek M, Lupo-Stanghellini MT, Kosasih PL, et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res. 2013 Jun 15 19(12):3153–3164. https://doi.org/10.1158/1078-0432.CCR-13-0330
- Specht J, Lee SM, Turtle C, et al. Abstract P2-09-13: a phase I study of adoptive immunotherapy for ROR1+ advanced triple negative breast cancer (TNBC) with defined subsets of autologous T cells expressing a ROR1-specific chimeric antigen receptor (ROR1-CAR). Cancer Res. 2019 February 15;79:2–09.
- Chen W, Zhang Z, Zhang S, et al. MUC1: structure, function, and clinic application in epithelial cancers. Int J Mol Sci. 2021 Jun 18;22(12):6567.
- Nath S, Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med. 2014 Jun;20(6):332–342.
- Zhou R, Yazdanifar M, Roy LD, et al. CAR T cells targeting the tumor muc1 glycoprotein reduce triple-negative breast cancer growth. Front Immunol. 2019;10:1149.
- Gutierrez R, Shah PD, Hamid O, et al. Phase I experience with first in class TnMUC1 targeted chimeric antigen receptor T-cells in patients with advanced TnMUC1 positive solid tumors. J clin oncol. 2021 [2021 may 20];39(15):e14513–e14513. DOI:https://doi.org/10.1200/JCO.2021.39.15_suppl.e14513.
- Posey AD Jr., Schwab RD, Boesteanu AC, et al. Engineered CAR T cells targeting the cancer-associated tn-glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity. 2016 Jun 21 44(6):1444–1454. https://doi.org/10.1016/j.immuni.2016.05.014
- Xu H, Niu M, Yuan X, et al. CD44 as a tumor biomarker and therapeutic target. Exp Hematol Oncol. 2020 Dec 10 9(1):36. https://doi.org/10.1186/s40164-020-00192-0
- Porcellini S, Asperti C, Corna S, et al. CAR T cells redirected to CD44v6 control tumor growth in lung and ovary adenocarcinoma bearing mice. Front Immunol. 2020;11:99.
- Osta WA, Chen Y, Mikhitarian K, et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res. 2004 Aug 15 64(16):5818–5824. https://doi.org/10.1158/0008-5472.CAN-04-0754
- Zhu C, Wei Y, Wei X. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019 Nov 4; 18(1):153. https://doi.org/10.1186/s12943-019-1090-3
- Zhang S, Xu XS, Yang JX, et al. The prognostic role of Gas6/Axl axis in solid malignancies: a meta-analysis and literature review. Onco Targets Ther. 2018;11:509–519.
- Wei J, Sun H, Zhang A, et al. A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers. Cell Immunol. 2018 Sep;331:49–58.
- Ye X, Li Y, Stawicki S, et al. An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene. 2010 Sep 23 29(38):5254–5264. https://doi.org/10.1038/onc.2010.268
- Brenig R, Pop OT, Triantafyllou E, et al. Expression of AXL receptor tyrosine kinase relates to monocyte dysfunction and severity of cirrhosis. Life Sci Alliance. 2020 Jan;3(1):e201900465. DOI:https://doi.org/10.26508/lsa.201900465.
- Scaranti M, Cojocaru E, Banerjee S, et al. Exploiting the folate receptor α in oncology. Nat Rev Clin Oncol. 2020 Jun;17(6):349–359. DOI:https://doi.org/10.1038/s41571-020-0339-5.
- Corti C, Giachetti P, Eggermont AMM, et al. Therapeutic vaccines for breast cancer: has the time finally come? Eur J Cancer. 2022 Jan;160:150–174.
- Song DG, Ye Q, Poussin M, et al. Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level. J Hematol Oncol. 2016 Jul 20 9(1):56. https://doi.org/10.1186/s13045-016-0285-y
- Lanitis E, Poussin M, Klattenhoff AW, et al. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res. 2013 Jul;1(1):43–53. DOI:https://doi.org/10.1158/2326-6066.CIR-13-0008.
- Kim MS, Ma JS, Yun H, et al. Redirection of genetically engineered CAR-T cells using bifunctional small molecules. J Am Chem Soc. 2015 Mar 4 137(8):2832–2835. https://doi.org/10.1021/jacs.5b00106
- Bravaccini S, Maltoni R. Trop-2 therapy in metastatic triple-negative breast cancer in italy: clinical opportunity and regulatory pitfalls. J Pers Med. 2021 Nov 16; 11(11):1211. https://doi.org/10.3390/jpm11111211
- Zhao W, Jia L, Zhang M, et al. The killing effect of novel bi-specific Trop2/PD-L1 CAR-T cell targeted gastric cancer. Am J Cancer Res. 2019;9(8):1846–1856.
- Hu Z. Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer. Sci Rep. 2020 Feb 18; 10(1):2815. https://doi.org/10.1038/s41598-020-59736-3
- Cheng J, Xu J, Duanmu J, et al. Effective treatment of human lung cancer by targeting tissue factor with a factor VII-targeted photodynamic therapy. Curr Cancer Drug Targets. 2011 Nov;11(9):1069–1081. DOI:https://doi.org/10.2174/156800911798073023.
- Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018 Jan;12(1):3–20.
- Lev S. Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis. Biochem Soc Trans. 2020;48(2):657–665.
- Liu Y, Zhou Y, Huang K-H, et al. EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC. Aging (Albany NY). 2019;11(23):11054–11072. DOI:https://doi.org/10.18632/aging.102510.
- Caratelli S, Sconocchia T, Arriga R, et al. FCγ chimeric receptor-engineered t cells: methodology, advantages, limitations, and clinical relevance. Front Immunol. 2017;8:457.
- Caratelli S, Arriga R, Sconocchia T, et al. In vitro elimination of epidermal growth factor receptor-overexpressing cancer cells by CD32A-chimeric receptor T cells in combination with cetuximab or panitumumab. Int J Cancer. 2020 Jan 1 146(1):236–247. https://doi.org/10.1002/ijc.32663
- Geldres C, Savoldo B, Hoyos V, et al. T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo. Clin Cancer Res. 2014 Feb 15 20(4):962–971. https://doi.org/10.1158/1078-0432.CCR-13-2218
- Harrer DC, Dörrie J, Schaft N. CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities-Merits and Challenges. Int J Mol Sci. 2019 Nov 26; 20(23):5942. https://doi.org/10.3390/ijms20235942
- Wiesinger M, März J, Kummer M, et al. Clinical-Scale Production of CAR-T Cells for the treatment of melanoma patients by mrna transfection of a cspg4-specific car under full gmp compliance. Cancers (Basel). 2019 Aug 16;11(8):1198.
- Park S, Shevlin E, Vedvyas Y, et al. Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity. Sci Rep. 2017 Oct 30 7(1):14366. https://doi.org/10.1038/s41598-017-14749-3
- Wei H, Wang Z, Kuang Y, et al. Intercellular Adhesion Molecule-1 as Target for CAR-T-cell therapy of triple-negative breast cancer. Front Immunol. 2020;11:573823.
- Høye AM, Tolstrup SD, Horton ER, et al. Tumor endothelial marker 8 promotes cancer progression and metastasis. Oncotarget. 2018 Jul 10 9(53):30173–30188. https://doi.org/10.18632/oncotarget.25734
- Chaudhary A, Hilton MB, Seaman S, et al. TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types. Cancer Cell. 2012 Feb 14 21(2):212–226. https://doi.org/10.1016/j.ccr.2012.01.004
- Cullen M, Seaman S, Chaudhary A, et al. Host-derived tumor endothelial marker 8 promotes the growth of melanoma. Cancer Res. 2009 Aug 1 69(15):6021–6026. https://doi.org/10.1158/0008-5472.CAN-09-1086
- Davies G, Rmali KA, Watkins G, et al. Elevated levels of tumour endothelial marker-8 in human breast cancer and its clinical significance. Int J Oncol. 2006 Nov;29(5):1311–1317.
- Chen D, Bhat-Nakshatri P, Goswami C, et al. ANTXR1, a stem cell-enriched functional biomarker, connects collagen signaling to cancer stem-like cells and metastasis in breast cancer. Cancer Res. 2013 Sep 15 73(18):5821–5833. https://doi.org/10.1158/0008-5472.CAN-13-1080
- Gutwein LG, Al-Quran SZ, Fernando S, et al. Tumor endothelial marker 8 expression in triple-negative breast cancer. Anticancer Res. 2011 Oct;31(10):3417–3422.
- Szot C, Saha S, Zhang XM, et al. Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release. J Clin Invest. 2018 Jul 2 128(7):2927–2943. https://doi.org/10.1172/JCI120481
- Byrd TT, Fousek K, Pignata A, et al. TEM8/ANTXR1-Specific CAR T cells as a targeted therapy for triple-negative breast cancer. Cancer Res. 2018 Jan 15 78(2):489–500. https://doi.org/10.1158/0008-5472.CAN-16-1911
- Petrovic K, Robinson J, Whitworth K, et al. TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo. PLoS One. 2019;14(10):e0224015. DOI:https://doi.org/10.1371/journal.pone.0224015.
- Sentman CL, Meehan KR. NKG2D CARs as cell therapy for cancer. Cancer J. 2014 Mar-Apr;20(2):156–159.
- Lehner M, Götz G, Proff J, et al. Redirecting T cells to Ewing’s sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. PLoS One. 2012;7(2):e31210. DOI:https://doi.org/10.1371/journal.pone.0031210.
- Nikiforow S, Werner L, Murad J, et al. safety data from a first-in-human phase 1 trial of NKG2D chimeric antigen receptor-T cells in AML/MDS and multiple myeloma. Blood. 2016 December 02;128:4052–4052. https://doi.org/10.1182/blood.V128.22.4052.4052.
- Whilding LM, Halim L, Draper B, et al. CAR T-cells targeting the integrin αvβ6 and co-expressing the chemokine receptor CXCR2 demonstrate enhanced homing and efficacy against several solid malignancies. Cancers (Basel). 2019 May 14 11(5):674. https://doi.org/10.3390/cancers11050674
- Di Stasi A, De Angelis B, Rooney CM, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009 Jun 18 113(25):6392–6402. https://doi.org/10.1182/blood-2009-03-209650
- Wang Y, Jiang H, Luo H, et al. An IL-4/21 inverted cytokine receptor improving CAR-T cell potency in immunosuppressive solid-tumor microenvironment [original research]. Front Immunol. 2019;10:1691.
- Hu W, Zi Z, Jin Y, et al. CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions. Cancer Immunol Immunother. 2019 Mar;68(3):365–377. DOI:https://doi.org/10.1007/s00262-018-2281-2.
- Yáñez L, Sánchez-Escamilla M, Perales MA. CAR T cell toxicity: current management and future directions. Hemasphere. 2019 Apr;3(2):e186.
- Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell Therapy. Cancer Discov. 2018 Oct;8(10):1219–1226.
- Antonarelli G, Corti C, Tarantino P, et al. Therapeutic cancer vaccines revamping: technology advancements and pitfalls. Ann Oncol. 2021 Dec;32(12):1537–1551. DOI:https://doi.org/10.1016/j.annonc.2021.08.2153.
- Abreu TR, Fonseca NA, Gonçalves N, et al. Current challenges and emerging opportunities of CAR-T cell therapies. J Control Release. 2020 Mar 10;319:246–261. https://doi.org/10.1016/j.jconrel.2019.12.047.
- Zhao Z, Li Y, Liu W, et al. Engineered IL-7 receptor enhances the therapeutic effect of AXL-CAR-T cells on triple-negative breast cancer. Biomed Res Int. 2020;2020:4795171.
- Klichinsky M, Ruella M, Shestova O, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020 Aug;38(8):947–953. DOI:https://doi.org/10.1038/s41587-020-0462-y.
- Wallstabe L, Mades A, Frenz S, et al. CAR T cells targeting α v β 3 integrin are effective against advanced cancer in preclinical models. Adv Cell Gene Ther. 2018 Sep;1(2):e11. https://doi.org/https://doi.org/10.1002/acg2.11
- Pantelidou C, Sonzogni O, De Oliveria Taveira M, et al. PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov. 2019 Jun;9(6):722–737. DOI:https://doi.org/10.1158/2159-8290.CD-18-1218.
- Zheng W, Jones LL, Geiger TL. Modulation of PI3K signaling to improve CAR T cell function. Oncotarget. 2018;92018:35807–35808.
- Yu JX, Upadhaya S, Tatake R, et al. Cancer cell therapies: the clinical trial landscape. Nat Rev Drug Discov. 2020;19(2020):583–584. England. DOI:https://doi.org/10.1038/d41573-020-00099-9.
- Saini KS, Svane IM, Juan M, et al. Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges. Ann Oncol. 2022 Jan;33(1):6–12. DOI:https://doi.org/10.1016/j.annonc.2021.09.020.
- Li R, Johnson R, Yu G, et al. Preservation of cell-based immunotherapies for clinical trials. Cytotherapy. 2019 Sep;21(9):943–957. DOI:https://doi.org/10.1016/j.jcyt.2019.07.004.
- Panch SR, Srivastava SK, Elavia N, et al. Effect of cryopreservation on autologous chimeric antigen receptor t cell characteristics. Mol Ther. 2019 Jul 3 27(7):1275–1285. https://doi.org/10.1016/j.ymthe.2019.05.015